Purchase this article with an account.
D. Moreno-Paramo, R. Velez-Montoya, J. Flores-Estrada, A. Rodriguez-Reyes, I. Hernandez-Ayuso, E. Torres Porras, E. Romo-Garcia, A. Hitos-Fajer, G. Garcia-Aguirre, H. Quiroz-Mercado; Intravitreal Rapamycin and Bevacizumab Inhibits VEGF Expression in a Swine Model of Neovascularization. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3457.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess if the association of intravitreal rapamycin and bevacizumab have an additive effect in decreasing vitreous VEGF levels more than bevacizumab alone. To assess the safety of intravitreal rapamycin in a porcine model of choroidal neovascularization.
We included eight eyes in the study. A choroidal neovascularization was created using argon laser shots. We divided the eyes in four groups: Group A (N=2) was injected with 1ml of intravitreal bevacizumab alone (2.25 mg/ml). Group B was injected with balanced saline solution, group C with 0.5ml of rapamycin (1mg/ml) and bevacizumab and group D just with rapamycin. The eyes were enucleated 21 days after the injections. We performed RT-PCR studies to all samples.
A decrease in VEGF expression in group A, C and D was observed. The most important reduction was observed in group A. No structural damage was detected in eyes injected with intravitreal rapamycin or bevacizumab.
Intravitreal rapamcin is safe for intravitreal administration with no structural alterations. The combination of rapamycin and bevacizumab is not better than bevacizumab alone in decreasing VEGF vitreous levels.
This PDF is available to Subscribers Only